Latest filing published 03 Apr 2017 for Asterias Biotherapeutics, Inc..
Insider track record
Closed purchases
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +35.0%Entry US$2.04 · Close at T+365 US$2.76
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Stephen LaHue Cartt: trading record in brief
Stephen LaHue Cartt is a declared insider at 3 companies; the most frequent names are Questcor Pharmaceuticals Inc, Asterias Biotherapeutics, Inc. and Lineage Cell Therapeutics, Inc. Between 30 November 2005 and 30 March 2017, the trades on record add up to 69 filings.
The open-market side counts 6 purchases for €527k alongside 22 sales for €14.3M. Taken together, the sales exceed the purchases by €13.8M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 16 share grants and 21 option exercises.
In size, the median ticket on the buying side is €73k. Ninety days after publication, 3 purchases show a median change of +37.2%, with the price up in 100% of them. This is a record of the past, not a forecast.
The latest filing, published on 3 April 2017, reports a share grant in Asterias Biotherapeutics, Inc. The last purchase on record was published on 1 July 2016, which is 3,782 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Stephen LaHue Cartt
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 32,783 shares0Common StockSEC:0001140361-17-014420:0
- 10,000 shares@ US$2.4014.3% of flowCommon StockSEC:0001140361-16-071335:0Canonical exit: 28 Sept 2016 (T+90)
- 50,000 shares@ US$2.9385.7% of flowCommon StockSEC:0001140361-16-069565:0Canonical exit: 8 Sept 2016 (T+90)
- 200,000 sharesCommon StockSEC:0001140361-16-055904:0
- 18,400 shares@ US$2.65Common Shares, no par valueSEC:0001209191-15-066702:0Canonical exit: 12 Nov 2015 (T+90)
- 39,400 shares@ US$2.83Common Shares, no par valueSEC:0001209191-15-066702:1Canonical exit: 15 Nov 2015 (T+90)
- 17,200 shares@ US$2.90Common Shares, no par valueSEC:0001209191-15-066702:2Canonical exit: 16 Nov 2015 (T+90)
- 109,785 sharesCommon StockSEC:0001209191-14-053199:0
- 46,250 sharesCommon StockSEC:0001209191-14-053199:1
- 23,000 sharesCommon StockSEC:0001209191-14-053199:2
- 23,000 shares0Common StockSEC:0001209191-14-014627:0
- 23,000 shares0Common StockSEC:0001209191-14-014627:1
- 20,667 shares0Common StockSEC:0001209191-14-014627:2
- 21,375 shares@ US$79.46Common StockSEC:0001209191-14-014627:3
- 24,879 shares0Common StockSEC:0001181431-13-022134:0
- 31,000 shares0Common StockSEC:0001181431-13-022134:1
- 31,000 shares0Common StockSEC:0001181431-13-022134:2
- 24,887 shares0Common StockSEC:0001181431-13-012901:0
- 31,000 shares0Common StockSEC:0001181431-13-012901:1
- 31,000 shares0Common StockSEC:0001181431-13-012901:2
- 10,000 shares@ US$24.17Common StockSEC:0001181431-12-057016:0Canonical exit: 31 Jan 2013 (T+90)
- 8,100 shares@ US$5.09Common StockSEC:0001181431-11-055828:0
- 8,100 shares@ US$42.75Common StockSEC:0001181431-11-055828:1
- 40,000 shares@ US$1.37Common StockSEC:0001181431-11-054180:0
- 21,877 shares@ US$1.37Common StockSEC:0001181431-11-054180:1
25 of 69 declarations